<p>在週五，<strong>拜瑪林製藥公司</strong> (NASDAQ: BMRN) 同意以總計約 48 億美元的股權價值收購 <strong>愛美醫療</strong> (NASDAQ: FOLD)。</p>
<p>“交易完成後，預計將加速拜瑪林的收入增長，並增強我們的財務前景，為患者、員工和股東帶來顯著價值。預計該交易將在完成後的前 12 個月對非公認會計原則稀釋每股收益產生積極影響，” 拜瑪林的總裁兼首席執行官亞歷山大·哈迪表示。</p>
<p><strong><em>另請閲讀: PTC Therapeutics 可能會對拜瑪林的代謝疾病治療構成挑戰</em></strong></p>
<h2>分析師觀點</h2>
<p><strong>Truist Securities</strong> 維持對拜瑪林的買入評級，並將 價格預測從 80 美元上調至 100 美元。</p>
<p><strong>威廉·布萊爾</strong> 對此次收購持積極態度，指出拜瑪林的產品組合中新增了兩種產生收入的罕見疾病療法。分析師 <strong>薩米·科爾温</strong> 認為這是一種強有力的戰略契合，強調與拜瑪林在罕見疾病和酶療法商業化方面的專業知識之間的明顯協同效應。</p>
<p>雖然該交易並未完全抵消來自競爭的 Voxzogo 收入壓力，但它顯著多樣化了拜瑪林的收入基礎，並且沒有臨牀開發風險。</p>
<p>威廉·布萊爾指出，Galafold 是一個更成熟的資產，這可能限制其增長，但相信拜瑪林的規模和擴展診斷及推動患者依從性的能力使公司能夠捕捉剩餘的上行空間。</p>
<p>分析師科爾温指出，龐貝病在全球大約影響每 1.8 萬人。管理層認為每個資產在 2030 年代可能產生約 10 億美元的峯值銷售，支持拜瑪林更強的長期收入增長。公司還預計運營協同效應將加速增長並提升淨利潤。</p>
<h2>技術分析</h2>
<p><strong>拜瑪林製藥公司</strong> (BMRN) 顯示出看漲的形態，因為其交易價格顯著高於短期移動平均線，表明積極的動能。</p>
<p>該股票目前的交易價格遠高於 20 日、50 日和 100 日簡單移動平均線，表明短期內的強勁表現。</p>
<p>相對強弱指數（RSI）為 65.54，屬於中性但接近超買區域。這個水平表明，儘管股票有上升動能，但交易者在接近超買閾值時應保持謹慎。</p>
<p>MACD 在其信號線之上，表明 BMRN 的看漲動能。這表明當前趨勢可能會持續，交易者可能會在短期內尋找進一步的上行空間。</p>
<p>關鍵支撐位在 52.50 美元，阻力位在 64.00 美元，這些都是需要關注的重要水平。如果股票接近這些水平，從支撐位反彈可能表明上漲趨勢的延續，而突破阻力位可能意味着更強的看漲走勢。</p>
<p>該股票在長期內一直面臨看跌趨勢，50 日簡單移動平均線低於 200 日簡單移動平均線。這個關係顯示，儘管短期內有強勁表現，但整體長期趨勢仍然承壓。</p>
<p>從 12 個月的表現來看，BMRN 下跌了 8.23%，反映出過去一年的挑戰。這一下降突顯了監測短期收益和更廣泛趨勢的重要性，以評估股票的未來潛力。</p>
<p>目前，BMRN 的交易價格為其 52 周區間的 44.3%，表明其接近該區間的下限。這一定位表明，儘管有增長空間，但交易者應意識到在突破阻力位時可能出現的波動性。</p>
<p>技術形態表明謹慎樂觀，但長期趨勢仍然是一個關鍵考慮因素。</p>
<p><strong>BMRN 價格動態：</strong> 根據 Benzinga Pro 的數據，拜瑪林製藥的股票在週二出版時上漲了 2.45%，報 59.37 美元。</p>
<p><strong>下一步閲讀：</strong></p>
<ul>
<li><strong><em>全球關鍵礦物依賴國際貿易，研究顯示關鍵脆弱性</em></strong></li>
</ul>
<p><em>圖片來源於 Shutterstock</em></p>

拜瑪林制藥

愛美醫療

<p>BioMarin 製藥公司（NASDAQ:BMRN）已同意以 48 億美元收購 Amicus Therapeutics, Inc.（NASDAQ:FOLD）。此次收購預計將加速 BioMarin 的收入增長，在 12 個月內對非 GAAP 攤薄每股收益產生積極影響，並使其收入基礎多樣化。分析師對這筆收購持積極態度，指出戰略協同效應和每項資產潛在的 10 億美元峯值銷售。BioMarin 的股票顯示出看漲勢頭，交易價格高於關鍵移動平均線，但面臨長期看跌壓力。週二，股價上漲 2.45%，至 59.37 美元</p>

<p>On Friday, <strong>BioMarin Pharmaceutical Inc.</strong> (NASDAQ: BMRN) agreed to acquire <strong>Amicus Therapeutics, Inc.</strong> (NASDAQ: FOLD) for a total equity value of about $4.8 billion.</p>
<div class="lb-trans"><p>在週五，<strong>拜瑪林製藥公司</strong> (NASDAQ: BMRN) 同意以總計約 48 億美元的股權價值收購 <strong>愛美醫療</strong> (NASDAQ: FOLD)。</p>
</div><p>&#34;Immediately upon close, this transaction is expected to accelerate BioMarin's revenue growth and strengthen our financial outlook, delivering significant value to patients, employees, and stockholders. The transaction is expected to be accretive to Non-GAAP Diluted EPS in the first 12 months following close,&#34; said Alexander Hardy, President and Chief Executive Officer of BioMarin.</p>
<div class="lb-trans"><p>“交易完成後，預計將加速拜瑪林的收入增長，並增強我們的財務前景，為患者、員工和股東帶來顯著價值。預計該交易將在完成後的前 12 個月對非公認會計原則稀釋每股收益產生積極影響，” 拜瑪林的總裁兼首席執行官亞歷山大·哈迪表示。</p>
</div><p><strong><em>Also Read: PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment</em></strong></p>
<div class="lb-trans"><p><strong><em>另請閲讀: PTC Therapeutics 可能會對拜瑪林的代謝疾病治療構成挑戰</em></strong></p>
</div><h2>Analyst Take</h2>
<div class="lb-trans"><h2>分析師觀點</h2>
</div><p><strong>Truist Securities</strong> maintains BioMarin with a Buy and raises the price forecast from $80 to $100.</p>
<div class="lb-trans"><p><strong>Truist Securities</strong> 維持對拜瑪林的買入評級，並將 價格預測從 80 美元上調至 100 美元。</p>
</div><p><strong>William Blair</strong> views the acquisition favorably, citing the addition of two revenue-generating rare disease therapies to BioMarin's portfolio. Analyst <strong>Sami Corwin</strong> sees a strong strategic fit, highlighting clear synergies with BioMarin's expertise in rare disease and enzyme therapy commercialization.</p>
<div class="lb-trans"><p><strong>威廉·布萊爾</strong> 對此次收購持積極態度，指出拜瑪林的產品組合中新增了兩種產生收入的罕見疾病療法。分析師 <strong>薩米·科爾温</strong> 認為這是一種強有力的戰略契合，強調與拜瑪林在罕見疾病和酶療法商業化方面的專業知識之間的明顯協同效應。</p>
</div><p>While the deal does not fully offset potential Voxzogo revenue pressure from competition, it meaningfully diversifies BioMarin's revenue base and carries no clinical development risk.</p>
<div class="lb-trans"><p>雖然該交易並未完全抵消來自競爭的 Voxzogo 收入壓力，但它顯著多樣化了拜瑪林的收入基礎，並且沒有臨牀開發風險。</p>
</div><p>William Blair notes that Galafold is a more mature asset, which may limit growth, but believes BioMarin's scale and proven ability to expand diagnosis and drive patient adherence position the company to capture the remaining upside.</p>
<div class="lb-trans"><p>威廉·布萊爾指出，Galafold 是一個更成熟的資產，這可能限制其增長，但相信拜瑪林的規模和擴展診斷及推動患者依從性的能力使公司能夠捕捉剩餘的上行空間。</p>
</div><p>Analyst Corwin notes that Pompe disease affects roughly 1 in 18,000 people worldwide. Management believes each asset could generate about $1 billion in peak sales in the 2030s, supporting stronger long-term revenue growth for BioMarin. The company also expects operational synergies to accelerate growth and lift net profits.</p>
<div class="lb-trans"><p>分析師科爾温指出，龐貝病在全球大約影響每 1.8 萬人。管理層認為每個資產在 2030 年代可能產生約 10 億美元的峯值銷售，支持拜瑪林更強的長期收入增長。公司還預計運營協同效應將加速增長並提升淨利潤。</p>
</div><h2>Technical Analysis</h2>
<div class="lb-trans"><h2>技術分析</h2>
</div><p><strong>BioMarin Pharmaceuticals Inc.</strong> (BMRN) is showing a bullish setup as it's trading significantly above its short-term moving averages, indicating positive momentum.</p>
<div class="lb-trans"><p><strong>拜瑪林製藥公司</strong> (BMRN) 顯示出看漲的形態，因為其交易價格顯著高於短期移動平均線，表明積極的動能。</p>
</div><p>The stock is currently positioned well above the 20-day, 50-day, and 100-day SMAs, suggesting strength in the near term.</p>
<div class="lb-trans"><p>該股票目前的交易價格遠高於 20 日、50 日和 100 日簡單移動平均線，表明短期內的強勁表現。</p>
</div><p>The RSI is at 65.54, which is considered neutral but close to overbought territory. This level indicates that while the stock has upward momentum, traders should remain cautious as it approaches the overbought threshold.</p>
<div class="lb-trans"><p>相對強弱指數（RSI）為 65.54，屬於中性但接近超買區域。這個水平表明，儘管股票有上升動能，但交易者在接近超買閾值時應保持謹慎。</p>
</div><p>MACD is above its signal line, signaling bullish momentum for BMRN. This suggests that the current trend could continue, and traders might look for further upside in the near term.</p>
<div class="lb-trans"><p>MACD 在其信號線之上，表明 BMRN 的看漲動能。這表明當前趨勢可能會持續，交易者可能會在短期內尋找進一步的上行空間。</p>
</div><p>Key support is at $52.50, and resistance is at $64.00, which are crucial levels to watch. If the stock approaches these levels, a bounce off support could indicate a continuation of the uptrend, while a break above resistance may signal a stronger bullish move.</p>
<div class="lb-trans"><p>關鍵支撐位在 52.50 美元，阻力位在 64.00 美元，這些都是需要關注的重要水平。如果股票接近這些水平，從支撐位反彈可能表明上漲趨勢的延續，而突破阻力位可能意味着更強的看漲走勢。</p>
</div><p>The stock has been struggling with a longer-term bearish trend, as indicated by the 50-day SMA being below the 200-day SMA. This relationship shows that while there is short-term strength, the overall longer-term trend remains under pressure.</p>
<div class="lb-trans"><p>該股票在長期內一直面臨看跌趨勢，50 日簡單移動平均線低於 200 日簡單移動平均線。這個關係顯示，儘管短期內有強勁表現，但整體長期趨勢仍然承壓。</p>
</div><p>Looking at the 12-month performance, BMRN is down 8.23%, reflecting challenges over the past year. This decline highlights the importance of monitoring both short-term gains and the broader trend to gauge the stock's future potential.</p>
<div class="lb-trans"><p>從 12 個月的表現來看，BMRN 下跌了 8.23%，反映出過去一年的挑戰。這一下降突顯了監測短期收益和更廣泛趨勢的重要性，以評估股票的未來潛力。</p>
</div><p>Currently, BMRN is trading at 44.3% of its 52-week range, indicating it is closer to the lower end of that range. This positioning suggests that while there is room for growth, traders should be aware of the potential for volatility as it attempts to break through resistance levels.</p>
<div class="lb-trans"><p>目前，BMRN 的交易價格為其 52 周區間的 44.3%，表明其接近該區間的下限。這一定位表明，儘管有增長空間，但交易者應意識到在突破阻力位時可能出現的波動性。</p>
</div><p>The technical setup suggests a cautious optimism, but the longer-term trend remains a key consideration.</p>
<div class="lb-trans"><p>技術形態表明謹慎樂觀，但長期趨勢仍然是一個關鍵考慮因素。</p>
</div><p><strong>BMRN Price Action:</strong> BioMarin Pharmaceutical shares were up 2.45% at $59.37 at the time of publication on Tuesday, according to Benzinga Pro data.</p>
<div class="lb-trans"><p><strong>BMRN 價格動態：</strong> 根據 Benzinga Pro 的數據，拜瑪林製藥的股票在週二出版時上漲了 2.45%，報 59.37 美元。</p>
</div><p><strong>Read Next</strong>:</p>
<div class="lb-trans"><p><strong>下一步閲讀：</strong></p>
</div><ul>
<li><strong><em>Global Critical Minerals Rely On International Trade, Study Shows Critical Vulnerabilities</em></strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong><em>全球關鍵礦物依賴國際貿易，研究顯示關鍵脆弱性</em></strong></li>
</ul>
</div><p><em>Photo via Shutterstock</em></p>
<div class="lb-trans"><p><em>圖片來源於 Shutterstock</em></p>
</div>

週二拜瑪林製藥的股票發生了什麼情況？